Pharsight

Vertex Pharms patents expiration

1. Incivek patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615 VERTEX PHARMS Dose forms
May, 2028

(4 years from now)

Drugs and Companies using TELAPREVIR ingredient

Market Authorisation Date: 23 May, 2011

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

INCIVEK family patents

Family Patents

2. Kalydeco patents expiration

KALYDECO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(2 years from now)

US7495103 VERTEX PHARMS Modulators of ATP-binding cassette transporters
May, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jun, 2025

(1 year, 2 months from now)

US8354427 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Jul, 2026

(2 years from now)

US8410274 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(2 years from now)

US9670163 VERTEX PHARMS Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(2 years from now)

US8324242 VERTEX PHARMS Modulators of ATP-binding cassette transporters
Aug, 2027

(3 years from now)

US10646481 VERTEX PHARMS Pharmaceutical composition and administrations thereof
Aug, 2029

(5 years from now)

US11564916 VERTEX PHARMS Pharmaceutical composition and administrations thereof
Aug, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2027

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 31 January, 2012

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in ...

Dosage: TABLET;ORAL

How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage

KALYDECO family patents

Family Patents